Literature DB >> 27604892

Enhanced Method for Diagnosing Pharmacometric Models: Random Sampling from Conditional Distributions.

Marc Lavielle1, Benjamin Ribba2.   

Abstract

PURPOSE: For nonlinear mixed-effects pharmacometric models, diagnostic approaches often rely on individual parameters, also called empirical Bayes estimates (EBEs), estimated through maximizing conditional distributions. When individual data are sparse, the distribution of EBEs can "shrink" towards the same population value, and as a direct consequence, resulting diagnostics can be misleading.
METHODS: Instead of maximizing each individual conditional distribution of individual parameters, we propose to randomly sample them in order to obtain values better spread out over the marginal distribution of individual parameters.
RESULTS: We evaluated, through diagnostic plots and statistical tests, hypothesis related to the distribution of the individual parameters and show that the proposed method leads to more reliable results than using the EBEs. In particular, diagnostic plots are more meaningful, the rate of type I error is correctly controlled and its power increases when the degree of misspecification increases. An application to the warfarin pharmacokinetic data confirms the interest of the approach for practical applications.
CONCLUSIONS: The proposed method should be implemented to complement EBEs-based approach for increasing the performance of model diagnosis.

Entities:  

Keywords:  model diagnostics; modeling and simulation; pharmacokinetics and pharmacodynamics

Mesh:

Substances:

Year:  2016        PMID: 27604892     DOI: 10.1007/s11095-016-2020-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  13 in total

1.  Goodness-of-fit in generalized nonlinear mixed-effects models.

Authors:  E F Vonesh; V M Chinchilli; K Pu
Journal:  Biometrics       Date:  1996-06       Impact factor: 2.571

2.  Automatic data binning for improved visual diagnosis of pharmacometric models.

Authors:  Marc Lavielle; Kevin Bleakley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-26       Impact factor: 2.745

Review 3.  Diagnosing model diagnostics.

Authors:  M O Karlsson; R M Savic
Journal:  Clin Pharmacol Ther       Date:  2007-07       Impact factor: 6.875

4.  Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.

Authors:  Radojka M Savic; Mats O Karlsson
Journal:  AAPS J       Date:  2009-08-01       Impact factor: 4.009

5.  Diagnosis of random-effect model misspecification in generalized linear mixed models for binary response.

Authors:  Xianzheng Huang
Journal:  Biometrics       Date:  2009-06       Impact factor: 2.571

6.  A new exact test for the evaluation of population pharmacokinetic and/or pharmacodynamic models using random projections.

Authors:  Celine Marielle Laffont; Didier Concordet
Journal:  Pharm Res       Date:  2011-04-14       Impact factor: 4.200

7.  Testing multiple variance components in linear mixed-effects models.

Authors:  Reza Drikvandi; Geert Verbeke; Ahmad Khodadadi; Vahid Partovi Nia
Journal:  Biostatistics       Date:  2012-08-28       Impact factor: 5.899

8.  Diagnostics for repeated measurements in linear mixed effects models.

Authors:  Jungwon Mun; Mary J Lindstrom
Journal:  Stat Med       Date:  2012-09-11       Impact factor: 2.373

9.  Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.

Authors:  Y Yano; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

10.  Powers of the likelihood ratio test and the correlation test using empirical bayes estimates for various shrinkages in population pharmacokinetics.

Authors:  F P Combes; S Retout; N Frey; F Mentré
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-04-09
View more
  26 in total

1.  Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase.

Authors:  John C Panetta; Yiwei Liu; Hope D Swanson; Seth E Karol; Ching-Hon Pui; Hiroto Inaba; Sima Jeha; Mary V Relling
Journal:  Pediatr Blood Cancer       Date:  2020-04-23       Impact factor: 3.167

2.  Bayesian Individual Dynamic Predictions with Uncertainty of Longitudinal Biomarkers and Risks of Survival Events in a Joint Modelling Framework: a Comparison Between Stan, Monolix, and NONMEM.

Authors:  François Riglet; France Mentre; Christine Veyrat-Follet; Julie Bertrand
Journal:  AAPS J       Date:  2020-02-19       Impact factor: 4.009

3.  Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.

Authors:  Paolo Denti; Anneke C Hesseling; Louvina E van der Laan; Anthony J Garcia-Prats; H Simon Schaaf; Tjokosela Tikiso; Lubbe Wiesner; Mine de Kock; Jana Winckler; Jennifer Norman; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

4.  Mathematical modelling identifies the role of adaptive immunity as a key controller of respiratory syncytial virus in cotton rats.

Authors:  Darren Wethington; Olivia Harder; Karthik Uppulury; William C L Stewart; Phylip Chen; Tiffany King; Susan D Reynolds; Alan S Perelson; Mark E Peeples; Stefan Niewiesk; Jayajit Das
Journal:  J R Soc Interface       Date:  2019-11-27       Impact factor: 4.118

5.  Kernel-Based Visual Hazard Comparison (kbVHC): a Simulation-Free Diagnostic for Parametric Repeated Time-to-Event Models.

Authors:  Sebastiaan C Goulooze; Pyry A J Välitalo; Catherijne A J Knibbe; Elke H J Krekels
Journal:  AAPS J       Date:  2017-11-27       Impact factor: 4.009

6.  Population Pharmacokinetic-Pharmacodynamic Modeling of Ropivacaine in Spinal Anesthesia.

Authors:  Zoubir Djerada; Catherine Feliu; Yoann Cazaubon; Faouzi Smati; Philippe Gomis; Dominique Guerrot; Beny Charbit; Olivier Fernandes; Jean-Marc Malinovsky
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

7.  Efficient Pharmacokinetic Modeling Workflow With the MonolixSuite: A Case Study of Remifentanil.

Authors:  Pauline Traynard; Géraldine Ayral; Monika Twarogowska; Jonathan Chauvin
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-03-31

8.  Steady-state population pharmacokinetics of terizidone and its metabolite cycloserine in patients with drug-resistant tuberculosis.

Authors:  Mwila Mulubwa; Pierre Mugabo
Journal:  Br J Clin Pharmacol       Date:  2019-07-12       Impact factor: 4.335

9.  Population pharmacokinetics of serelaxin in patients with acute or chronic heart failure, hepatic or renal impairment, or portal hypertension and in healthy subjects.

Authors:  Antoine Soubret; Yinuo Pang; Jing Yu; Marion Dahlke
Journal:  Br J Clin Pharmacol       Date:  2018-08-23       Impact factor: 4.335

10.  PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT.

Authors:  Andrea Henrich; Pierre-Eric Juif; Jasper Dingemanse; Andreas Krause
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-01-02       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.